Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its project to advance a robotic aseptic fill & finish platform has been approved for expanded support by the Israel Innovation Authority. The approval allows the company to utilize the full approved grant budget of NIS 5 million over two years, with approximately 66% representing non-dilutive funding.
The program specifically supports the acquisition and validation of a fully automated robotic-arm aseptic fill & finish system aligned with EU GMP Annex 1 standards. Validation of this advanced manufacturing system is targeted for completion by the third quarter of 2026. This technological advancement represents a significant step forward in sterile biologics manufacturing capabilities within the contract development and manufacturing organization sector.
This investment supports Scinai's broader CDMO expansion strategy, which has been strengthened through its acquisition of Recipharm Israel Ltd. and subsequent commercial collaboration with Recipharm. The company operates two manufacturing sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne. Through its strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm's global network, enabling continuity of development, streamlined tech transfer, and reduced scale-up risk as programs advance.
The expanded grant support enables Scinai to enhance its integrated two-site manufacturing platform while maintaining disciplined capital allocation through maximized non-dilutive funding. For business and technology leaders in the pharmaceutical and biotechnology sectors, this development signals increasing automation and precision in biologics manufacturing, potentially reducing contamination risks and improving production efficiency for critical therapies.
The company's CDMO unit provides comprehensive fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies, supporting external clients from preclinical development through Phase I/II clinical supply. Services include biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization. The CDMO primarily engages with early-stage and emerging biotech companies and mid-size pharmaceutical companies outsourcing early development programs.
In parallel with its CDMO operations, Scinai continues to advance a focused immunology pipeline through its R&D unit, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is actively seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation. Additional information about the company is available through its newsroom at https://ibn.fm/SCNI.
